One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema

PURPOSE: Conbercept is a novel recombinant fusion protein designed as a decoy receptor for vascular endothelial growth factor (VEGF) and placental growth factor. The primary purpose was to investigate the effect and safety of conbercept, based on a practical protocol, in the eyes of patients with di...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Qingyun, Guo, Chao, You, Ailing, Wang, Desai, Wang, Wenyan, Zhang, Xuedong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Vision 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817735/
https://www.ncbi.nlm.nih.gov/pubmed/31700228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817735/
https://www.ncbi.nlm.nih.gov/pubmed/31700228

Ejemplares similares